Chemomab Therapeutics Ltd. Deferred Tax Assets, Operating Loss Carryforwards
Chemomab Therapeutics Ltd. (CMMB) had Deferred Tax Assets, Operating Loss Carryforwards of $44.46 million as of 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Notes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-23
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $44.46M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $40.76M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $38.26M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $36.55M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $44.46M 20-F · filed 2026-03-23 | |
| 2024-12-31 | $40.76M 20-F · filed 2026-03-23 | |
| 2023-12-31 | $38.26M 20-F · filed 2025-04-04 | |
| 2022-12-31 | $36.55M 20-F · filed 2025-04-04 | |
| 2021-12-31 | $33.40M 20-F · filed 2024-03-28 | |
| 2020-12-31 | $4.87M 10-K · filed 2022-03-30 | $24.65M 10-K · filed 2021-03-09 |
| 2019-12-31 | $17.81M 10-K · filed 2021-03-09 | |
| 2018-12-31 | $14.03M 10-K · filed 2020-03-17 |